Healthcare of Ontario Pension Plan Trust Fund Lowers Holdings in IDEXX Laboratories, Inc. $IDXX

Healthcare of Ontario Pension Plan Trust Fund trimmed its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 22.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 97,610 shares of the company’s stock after selling 28,555 shares during the period. Healthcare of Ontario Pension Plan Trust Fund owned about 0.12% of IDEXX Laboratories worth $66,036,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also made changes to their positions in IDXX. Empowered Funds LLC lifted its position in shares of IDEXX Laboratories by 6.6% in the first quarter. Empowered Funds LLC now owns 1,538 shares of the company’s stock valued at $646,000 after acquiring an additional 95 shares in the last quarter. Sivia Capital Partners LLC purchased a new position in shares of IDEXX Laboratories in the second quarter valued at about $265,000. Jump Financial LLC lifted its position in shares of IDEXX Laboratories by 1,006.4% in the second quarter. Jump Financial LLC now owns 5,532 shares of the company’s stock valued at $2,967,000 after acquiring an additional 5,032 shares in the last quarter. Cary Street Partners Financial LLC purchased a new position in shares of IDEXX Laboratories in the second quarter valued at about $164,000. Finally, Sei Investments Co. lifted its position in shares of IDEXX Laboratories by 218.7% in the second quarter. Sei Investments Co. now owns 120,587 shares of the company’s stock valued at $64,678,000 after acquiring an additional 82,755 shares in the last quarter. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

IDEXX Laboratories Price Performance

NASDAQ:IDXX opened at $560.88 on Monday. The company has a current ratio of 1.12, a quick ratio of 0.82 and a debt-to-equity ratio of 0.19. The company has a market capitalization of $44.24 billion, a P/E ratio of 41.30, a P/E/G ratio of 3.07 and a beta of 1.56. IDEXX Laboratories, Inc. has a 12 month low of $506.91 and a 12 month high of $769.98. The business’s 50-day moving average is $563.06 and its 200 day moving average is $626.82.

IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Tuesday, May 5th. The company reported $3.47 EPS for the quarter, topping analysts’ consensus estimates of $3.41 by $0.06. The company had revenue of $1.14 billion for the quarter, compared to the consensus estimate of $1.12 billion. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The firm’s revenue for the quarter was up 14.3% on a year-over-year basis. During the same period in the previous year, the business earned $2.91 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. On average, equities research analysts forecast that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently commented on IDXX shares. Stifel Nicolaus lowered their price objective on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a research report on Tuesday, March 31st. UBS Group lowered their price objective on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a research report on Tuesday, April 28th. Citigroup initiated coverage on IDEXX Laboratories in a research report on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 price objective on the stock. Weiss Ratings downgraded IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 11th. Finally, Wall Street Zen upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating in a research report on Saturday. Seven investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $751.00.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.